Jiangsu Nhwa Pharmaceutical (002262.SZ): Class 1 innovative drug NH302 injection has been approved to conduct clinical trials.
Enhua Pharmaceutical (002262.SZ) announced that it has recently received the "Drug Clinical Trial Approval Notice" for the Class 1 chemical drug NH302 injection, issued by the National Medical Products Administration, and will soon commence clinical trials. NH302 is a peripheral-selective Kappa receptor agonist. Preclinical trial results indicate that NH302 has strong agonistic activity on Kappa receptors and demonstrates good analgesic effects across multiple pain animal models, with a low effective dose, prolonged duration of action, and a large sedation safety window, showing promise for development as a treatment for acute pain with significant clinical advantages.
Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the company has recently received the "Notice of Approval for Clinical Trial of Drugs" from the National Medical Products Administration for its Class 1 chemical drug NH302 injection, and will begin clinical trials in the near future. NH302 is a peripherally selective Kappa receptor agonist. Preclinical trial results indicate that NH302 has a strong agonistic activity on Kappa receptors and demonstrates good analgesic effects in multiple pain animal models, with a low effective dose, long duration of action, and a wide safety window, showing promise for development as a drug for acute pain treatment with significant clinical advantages.
Related Articles
Kanglong CHINAPROPERTIES (06968) had a contract sales amount of approximately 814.2 million yuan in the first seven months, representing a year-on-year decrease of 74.16%.
PRINX CHENGSHAN (01809) announced its interim results, with shareholders' net profit of 414 million yuan, a decrease of 18.5% year-on-year.
BAWANG GROUP (01338) issues a profit warning, expecting half-year profits of about 1 million to 2 million yuan, turning from loss to profit year-on-year.
Kanglong CHINAPROPERTIES (06968) had a contract sales amount of approximately 814.2 million yuan in the first seven months, representing a year-on-year decrease of 74.16%.
PRINX CHENGSHAN (01809) announced its interim results, with shareholders' net profit of 414 million yuan, a decrease of 18.5% year-on-year.
BAWANG GROUP (01338) issues a profit warning, expecting half-year profits of about 1 million to 2 million yuan, turning from loss to profit year-on-year.
RECOMMEND
